Skip to content

Study · Not a test of the peptide alone · 2017

3 results

Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).

Leder BZ, Tsai JN, Jiang LA, Lee H

Bone9 Mar 2017Cited by 78 (Europe PMC)

PMID28286299 (opens in a new tab)DOI10.1016/j.bone.2017.03.006 (opens in a new tab)PepBankPUB-28286299
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Among untreated women, discontinuing teriparatide was associated with less femoral neck BMD loss than discontinuing denosumab.

    In plain wordsAmong untreated women, stopping teriparatide was linked to less femoral neck bone loss than stopping denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck BMD by discontinued drug
    Study

    n = 22

    Comparator
    Discontinuing denosumab
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Femoral neck BMD change
    −5.8%
    untreated women discontinuing denosumab
    Femoral neck BMD change
    −0.8%
    untreated women discontinuing teriparatide

    Source sentences

    Summary
    Among untreated women, femoral neck BMD decreased more in those discontinuing denosumab (-5.8±4.0%) than in those discontinuing teriparatide (-0.8±2.6%, P=0.008).
    2 context sentences
    Summary · context
    In these studies, women received 2-years of either teriparatide, denosumab or both medications followed by 2-years of the alternate therapy (women who received combination therapy initially received an additional 2-years of denosumab alone).
    Summary · context
    Fifty of 69 women who completed DATA-Switch returned after a mean of 15.4±3.5months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Among untreated women, discontinuing teriparatide was associated with less total hip BMD loss than discontinuing denosumab.

    In plain wordsAmong untreated women, stopping teriparatide was linked to less hip bone loss than stopping denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal hip BMD by discontinued drug
    Study

    n = 22

    Comparator
    Discontinuing denosumab
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Total hip BMD, but not spine BMD, showed a similar pattern.
    3 context sentences
    Summary · context
    Among untreated women, femoral neck BMD decreased more in those discontinuing denosumab (-5.8±4.0%) than in those discontinuing teriparatide (-0.8±2.6%, P=0.008).
    Summary · context
    In these studies, women received 2-years of either teriparatide, denosumab or both medications followed by 2-years of the alternate therapy (women who received combination therapy initially received an additional 2-years of denosumab alone).
    Summary · context
    Fifty of 69 women who completed DATA-Switch returned after a mean of 15.4±3.5months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Among untreated women, spine BMD did not show the differential loss pattern seen after discontinuing teriparatide versus denosumab at other sites.

    In plain wordsAmong untreated women, spine bone loss did not show the difference seen between stopping teriparatide and stopping denosumab at the hip.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSpine BMD by discontinued drug
    Study

    n = 22

    Comparator
    Discontinuing denosumab
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Total hip BMD, but not spine BMD, showed a similar pattern.
    3 context sentences
    Summary · context
    Among untreated women, femoral neck BMD decreased more in those discontinuing denosumab (-5.8±4.0%) than in those discontinuing teriparatide (-0.8±2.6%, P=0.008).
    Summary · context
    In these studies, women received 2-years of either teriparatide, denosumab or both medications followed by 2-years of the alternate therapy (women who received combination therapy initially received an additional 2-years of denosumab alone).
    Summary · context
    Fifty of 69 women who completed DATA-Switch returned after a mean of 15.4±3.5months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.